Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.

IF 7.2 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2026-07-06 DOI:10.1038/s41541-026-01511-y

Pavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, Lucian Gaianu, Gaurav Mathur, Piotr Wojciechowski, Thatiana Pinto, Tia Vincent, Helen Petousis-Harris, Terry Nolan, Federico Martinón-Torres, Lee H Harrison, Zeki Kocaata

{"title":"Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.","authors":"Pavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, Lucian Gaianu, Gaurav Mathur, Piotr Wojciechowski, Thatiana Pinto, Tia Vincent, Helen Petousis-Harris, Terry Nolan, Federico Martinón-Torres, Lee H Harrison, Zeki Kocaata","doi":"10.1038/s41541-026-01511-y","DOIUrl":null,"url":null,"abstract":"<p><p>4CMenB vaccine is authorized for protection against serogroup B invasive meningococcal disease (IMD). This study synthesized real-world evidence (RWE) data on effectiveness and impact of 4CMenB vaccine. A systematic search identified RWE on vaccine effectiveness (VE) and vaccine impact of 4CMenB in infants, children and adolescents. A meta-analysis was conducted of 4CMenB VE against serogroup B-IMD in infants and children. The primary meta-analysis used a random-effects model on data from five studies from five countries reporting VE in fully vaccinated infants and children, and estimated pooled VE at 79.7% (95% confidence interval 70.4, 86.1). In sensitivity analyzes, inclusion/exclusion of studies from the primary analysis did not materially change the results. Age-specific data in adolescents were summarized qualitatively. Data identified from Australia reported high effectiveness and impact in adolescents. This meta-analysis provides evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children across different geographic regions. Clinical trial registration: N/A.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401604/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-026-01511-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

4CMenB vaccine is authorized for protection against serogroup B invasive meningococcal disease (IMD). This study synthesized real-world evidence (RWE) data on effectiveness and impact of 4CMenB vaccine. A systematic search identified RWE on vaccine effectiveness (VE) and vaccine impact of 4CMenB in infants, children and adolescents. A meta-analysis was conducted of 4CMenB VE against serogroup B-IMD in infants and children. The primary meta-analysis used a random-effects model on data from five studies from five countries reporting VE in fully vaccinated infants and children, and estimated pooled VE at 79.7% (95% confidence interval 70.4, 86.1). In sensitivity analyzes, inclusion/exclusion of studies from the primary analysis did not materially change the results. Age-specific data in adolescents were summarized qualitatively. Data identified from Australia reported high effectiveness and impact in adolescents. This meta-analysis provides evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children across different geographic regions. Clinical trial registration: N/A.

查看原文本刊更多论文

4CMenB疫苗对血清B群侵袭性脑膜炎球菌病的实际有效性和影响：系统回顾和荟萃分析

cmenb疫苗被批准用于预防血清B群侵袭性脑膜炎球菌病（IMD）。本研究综合了4CMenB疫苗有效性和影响的真实证据（RWE）数据。一项系统搜索确定了4CMenB在婴儿、儿童和青少年中的疫苗有效性（VE）和疫苗影响的RWE。对4CMenB VE对婴儿和儿童血清B-IMD进行了荟萃分析。主要荟萃分析使用随机效应模型对来自五个国家的五项研究的数据进行分析，这些研究报告了完全接种疫苗的婴儿和儿童的VE，估计合并VE为79.7%（95%置信区间为70.4,86.1）。在敏感性分析中，从主要分析中纳入/排除研究并没有实质性地改变结果。对青少年特定年龄的数据进行定性总结。来自澳大利亚的数据报告了对青少年的高有效性和影响。这项荟萃分析提供了证据，证明在不同地理区域完全接种疫苗的婴儿和儿童中，血清B-IMD的4CMenB VE水平较高。临床试验注册：无。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.